CAS 1428935-60-7

Durvalumab

Description:

Durvalumab is a monoclonal antibody that functions as an immune checkpoint inhibitor, specifically targeting the programmed death-ligand 1 (PD-L1). It is primarily used in the treatment of various cancers, including non-small cell lung cancer and bladder cancer. The mechanism of action involves blocking the interaction between PD-L1 and its receptors, PD-1 and CD80, thereby enhancing T-cell activation and promoting an immune response against tumor cells. Durvalumab is administered via intravenous infusion and is characterized by its high specificity and affinity for PD-L1. Its molecular structure includes a human IgG1 framework, which contributes to its stability and prolonged half-life in circulation. Common side effects associated with durvalumab treatment may include fatigue, cough, and immune-related adverse events, reflecting its role in modulating the immune system. As an investigational drug, durvalumab has undergone extensive clinical trials to establish its efficacy and safety profile, contributing to its approval for therapeutic use in oncology.

Formula: Unspecified

Synonyms:

• MED 14736
• Immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MEDI4736 heavy chain), disulfide with human monoclonal MEDI4736 κ-chain, dimer
• Durvalumab
• MEDI 4736
• Immunoglobulin G1, anti-(human protein B7-H1) (human monoclonal MEDI4736 heavy chain), disulfide with human monoclonal MEDI4736 κ-chain, dimer

Durvalumab

CAS: 1428935-60-7

Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.

Purity: 95% - 97.2% (SDS-PAGE); 95.3% (SEC-HPLC)

Color and Shape: Liquid

Molecular weight: 146.03 kDa

Ref: TM-T11126

Durvalumab

CAS: 1428935-60-7

Durvalumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that binds to PD-L1, a protein expressed on the surface of tumor cells. Durvalumab is being studied in combination with tremelimumab (another anti-PD-L1 antibody) for use as an antitumor agent. The combination of durvalumab and tremelimumab has been shown to have an antitumor response in mice with bowel disease. This drug has been shown to have an immune-modulating effect in combination therapy groups.

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 1,000 g/mol

Ref: 3D-DHC93560